Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancer

References

• Yap TA, Jacobs I, Baumfeld Andre E, et al. Application of real-world data to external control groups in oncology clinical trial drug development. Front Oncol. 2021;11:695936. doi: 10.3389/fonc.2021.695936.
   PubMed Web of Science ®Google Scholar
• Carrigan G, Bradbury BD, Brookhart MA, et al. External comparator groups derived from real-world data used in support of regulatory decision making: use cases and challenges. Curr Epidemiol Rep. 2022;9(4):326–337. doi: 10.1007/s40471-022-00305-9.
   Google Scholar
• Goring S, Taylor A, Müller K, et al. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review. BMJ Open. 2019;9(2):e024895. doi: 10.1136/bmjopen-2018-024895.
   PubMed Web of Science ®Google Scholar
• Carrigan G, Whipple S, Capra WB, et al. Using electronic health records to derive control arms for early phase single-arm lung cancer trials: proof-of-concept in randomized controlled trials. Clin Pharmacol Ther. 2020;107(2):369–377. doi: 10.1002/cpt.1586.
   PubMed Web of Science ®Google Scholar
• Jemielita T, Widman L, Fox C, et al. Replication of oncology randomized trial results using Swedish registry real world-data: a feasibility study. Clin Pharmacol Ther. 2021;110(6):1613–1621. doi: 10.1002/cpt.2424.
   PubMed Web of Science ®Google Scholar
• Enerly E, Holmstrøm L, Skog A, et al. INSPIRE: a new opportunity for cancer pharmacoepidemiology research. Nor J Epidemiol. 2021;29(1-2):29–33. doi: 10.5324/nje.v29i1-2.4043.
   Google Scholar
• Annual Quality Report Lung cancer. 2021. The Cancer Registry of Norway: 2022.
   Google Scholar
• Bakken IJ, Ariansen AMS, Knudsen GP, et al. The norwegian patient registry and the norwegian registry for primary health care: research potential of two nationwide health-care registries. Scand J Public Health. 2020;48(1):49–55. doi: 10.1177/1403494819859737.
   PubMed Web of Science ®Google Scholar
• Hva er legemiddelregisteret. Norwegian Institute of Public HealthNorwegian Institute of Public Health; 2022 cited 2023 May 30]. Available from: https://www.fhi.no/he/legemiddelregisteret/om-legemiddelregisteret/.
   Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi: 10.1056/NEJMoa1810865.
   PubMed Web of Science ®Google Scholar
• Cancer in Norway 2021 - Cancer incidence, mortality, survival and prevalence in Norway. The Cancer Registry of Norway: 2022.
   Google Scholar
• Azam, Latif F, Farooq MF, et al. Performance status assessment by using ECOG (Eastern cooperative oncology group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol. 2019;12(3):728–736. doi: 10.1159/000503095.
   PubMed Web of Science ®Google Scholar
• Dall’Olio FG, Maggio I, Massucci M, et al. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors – a systematic review and meta-analysis of real world data. Lung Cancer. 2020;145:95–104. doi: 10.1016/j.lungcan.2020.04.027.
   PubMed Web of Science ®Google Scholar
• Cramer-van der Welle CM, Peters BJM, Schramel F, et al. Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic non-small cell lung cancer. Eur Respir J. 2018;52(6):1801100. doi: 10.1183/13993003.01100-2018.
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Baker S, Temin S, et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27(36):6251–6266. doi: 10.1200/JCO.2009.23.5622.
   PubMed Web of Science ®Google Scholar
• Helbekkmo N, Sundstrøm SH, Aasebø U, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer. 2007;97(3):283–289. doi: 10.1038/sj.bjc.6603869.
   PubMed Web of Science ®Google Scholar
• Mishra-Kalyani PS, Amiri Kordestani L, Rivera DR, et al. External control arms in oncology: current use and future directions. Ann Oncol. 2022;33(4):376–383. doi: 10.1016/j.annonc.2021.12.015.
   PubMed Web of Science ®Google Scholar
• Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18(22):6169–6177. doi: 10.1158/1078-0432.CCR-11-3265.
   PubMed Web of Science ®Google Scholar
• Tan YY, Papez V, Chang WH, et al. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev. 2022;3(10):e674–e89. doi: 10.1159/000503095.
   PubMedGoogle Scholar